title: Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans.
abstract: To determine safety and immunogenicity, a single 0.5 ml dose of a monovalent live-attenuated dengue (DEN) 4 (341750 Carib) vaccine was given sc to 3 groups of flavivirus nonimmune volunteers in increasing concentrations. Two recipients received 10(3) plaque forming units (PFU)/dose (1:100 dilution of stock vaccine). One remained asymptomatic, but became viremic between days 12 and 15, experienced a mild elevation of temperature (37.4 degrees C), and developed DEN-4 specific antibody. Neither recipient of the 10(4) PFU became infected. Eight volunteers then received undiluted vaccine (10(5) PFU). Viremia and antibody (neutralizing, hemagglutination inhibition, and IgM) developed in 5 of the 8 (63%). These 5 volunteers also developed a scarcely noticeable macular, blanching rash and minimal temperature elevations (37.3, 38.1, 37, 37.9, and 37.9 degrees C). Clinically insignificant decreases in total white blood cell, lymphocyte, and polymorphonuclear cell counts and an elevation in mononuclear cell counts occurred in association with viremia. This vaccine is safe, reasonably immunogenic, and suitable for further evaluation.
authors.affiliation: Walter Reed Army Institute of Research, Washington, DC.
authors.forename: C H
authors.initials: CH
authors.lastname: Hoke
authors.forename: F J
authors.initials: FJ
authors.lastname: Malinoski
authors.forename: K H
authors.initials: KH
authors.lastname: Eckels
authors.forename: R M
authors.initials: RM
authors.lastname: Scott
authors.forename: D R
authors.initials: DR
authors.lastname: Dubois
authors.forename: P L
authors.initials: PL
authors.lastname: Summers
authors.forename: T
authors.initials: T
authors.lastname: Simms
authors.forename: J
authors.initials: J
authors.lastname: Burrous
authors.forename: S E
authors.initials: SE
authors.lastname: Hasty
authors.forename: W H
authors.initials: WH
authors.lastname: Bancroft
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis*; D003715:Dengue / Q000209:etiology; D003716:Dengue Virus / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D015151:Immunoblotting; D007074:Immunoglobulin G / Q000096:biosynthesis; D007075:Immunoglobulin M / Q000096:biosynthesis; D007958:Leukocyte Count; D008297:Male; D009500:Neutralization Tests; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology / Q000592:standards; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology* / Q000592:standards; D014766:Viremia / Q000209:etiology
chemical_list: D000914:Antibodies, Viral; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D014613:Vaccines, Attenuated; D014765:Viral Vaccines